Syros Pharmaceuticals Inc expected to post a loss of $1.09 a share - Earnings Preview

Syros Pharmaceuticals

08/05/2023 18:25

* Syros Pharmaceuticals Inc  SYRS.OQ   SYRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 10. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 40.4% decrease in revenue to $3.26 million from $5.47 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Syros
Pharmaceuticals Inc
is for a loss of $1.09 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $16​, above​ its last closing price
of $3.15. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -1.36       -1.35      -0.17     Beat    87.4
 Sep. 30 2022  -3.91       -4.01      -3.21     Beat    20
 Jun. 30 2022  -3.92       -4.08      -5.40     Missed  -32.4​
 Mar. 31 2022  -4.64       -4.70      -4.00     Beat    14.9
 ​​Dec.        -4.50       -4.66      -3.80     Beat    18.4
 31 2021                                                
 Sep. 30 2021  -4.41       -4.40      -4.10     Beat    6.8​
 Jun. 30 2021  -3.70       -3.72      -3.60     Beat    3.3
 Mar. 31 2021  -4.57       -4.65      -2.30     Beat    50.5
 This summary was machine generated May 8 at 17:25 GMT.  All
figures in US dollars  unless otherwise stated